Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium (Q38099195)

28 August 2017

title

Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium (English)

1 reference

28 August 2017

1 reference

D Tweedie

1

1 reference

28 August 2017

J W Polli

2

1 reference

28 August 2017

E Gil Berglund

3

1 reference

28 August 2017

S M Huang

4

1 reference

28 August 2017

L Zhang

5

1 reference

28 August 2017

A Poirier

6

1 reference

28 August 2017

X Chu

7

1 reference

28 August 2017

B Feng

8

1 reference

28 August 2017

International Transporter Consortium

9

1 reference

28 August 2017

language of work or name

English

0 references

publication date

10 April 2013

1 reference

Clinical Pharmacology & Therapeutics

28 August 2017

published in

1 reference

28 August 2017

volume

94

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

113-125

1 reference

Membrane transporters in drug development

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Intracellular drug concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

The UCSF-FDA TransPortal: a public drug transporter database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Emerging transporters of clinical importance: an update from the International Transporter Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Review of P-gp inhibition data in recently approved new drug applications: utility of the proposed [I(1) ]/IC(50) and [I(2) ]/IC(50) criteria in the P-gp decision tree

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

The role of physiologically based pharmacokinetic modeling in regulatory review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Breast cancer resistance protein in pharmacokinetics and drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin a in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

Highlights from the International Transporter Consortium second workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

7 January 2021

A regulatory viewpoint on transporter-based drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

7 January 2021

Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

7 January 2021

An overview of transporter information in package inserts of recently approved new molecular entities

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

7 January 2021

Communication between multiple drug binding sites on P-glycoprotein

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

7 January 2021

Substrate- and species-dependent inhibition of P-glycoprotein-mediated transport: implications for predicting in vivo drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

7 January 2021

Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.77

7 January 2021

Identifiers

DOI

10.1038/CLPT.2013.77

1 reference

Dimensions Publication ID

28 August 2017

1001504326

0 references

1 reference